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MitoferrinIron plays an essential role in cellular metabolism and biological processes. However, due to its intrinsic
redox activity, free iron is a potentially toxic molecule in cellular biochemistry. Thus, organisms have devel-
oped sophisticated ways to import, sequester, and utilize iron. The transferrin cycle is a well-studied iron up-
take pathway that is important for most vertebrate cells. Circulating iron can also be imported into cells by
mechanisms that are independent of transferrin. Once imported into erythroid cells, iron is predominantly
consumed by the mitochondria for the biosynthesis of heme and iron sulfur clusters. This review focuses
on canonical transferrin-mediated and the newly discovered, non-transferrin mediated iron uptake path-
ways, as well as, mitochondrial iron homeostasis in higher eukaryotes. This article is part of a Special Issue
entitled: Cell Biology of Metals.
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Iron is a cofactor that plays critical roles in numerous biolog-
ical processes including oxygen transport, electron transport, gas
sensing and DNA synthesis. Despite its essential role for all eu-
karyotes, free iron is highly toxic due to its intrinsic ability to
generate free radicals through Fenton reactions. Thus, organisms
have developed sophisticated pathways to import, chaperone, se-
quester, and export this metal ion. Disruption of iron homeostasis
leads to either iron deﬁciency or iron overload and contributes to
such medical problems as anemia, hemochromatosis, and neuro-
degenerative disorders [1,2]. Research over the past decade has
led to a detailed description of many molecules involved in the
transport of iron. In this review, we will focus on both canonical
and noncanonical iron uptake pathways as well as mitochondrial
iron homeostasis in vertebrates. For iron metabolism in yeast and
plants, we refer readers to reviews by Drs. Caroline Philpott and
Mary Lou Guerinot in this issue, respectively.
Vertebrates have high requirements for iron, the majority of
which is used by red blood cells for hemoglobin production. In
humans, although all tissues have a requirement for iron, 65% to
75% of the total body iron is present as heme iron in erythrocytes
[3]. Under normal condition, the body iron is derived exclusively
from dietary iron through intestinal absorption. It has been proposediology of Metals.
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rights reserved.that dietary iron is reduced by the duodenal ferric reductases, such as
Dcytb [4]; however, the deﬁciency of Dcytb in engineered knockout
mice had no impact on body iron stores, even in the setting of iron de-
ﬁciency, suggesting that other mechanisms must be available for the
reduction of dietary iron [5]. Iron in the intestinal lumen is trans-
ported into the enterocytes by the divalent metal transporter DMT1
[6,7]. A fraction of iron is sequestered in the iron storage protein fer-
ritin, while the rest is translocated into the bloodstream by the iron
exporter ferroportin1 [8–10]. Ferrous iron in the circulation is oxi-
dized by ceruloplasmin or hephaestin followed by association with
the high-afﬁnity iron binding protein transferrin (Tf).2. Iron uptake through transferrin cycle
Iron uptake through transferrin–transferrin receptor (Tf–TfR) sys-
tem is essential for maintaining the body iron homeostasis (Fig. 1; see
also reviews [11–13]). Besides intestinal absorption, iron recycled
from senescent red blood cells contributes signiﬁcantly to the Tf iron
pool. Normally, almost all serum iron is bound to Tf. Iron-loaded Tf
(diferric Tf) binds to the Tf receptor (TfR) on cell surface, and the com-
plexes are endocytosed through clathrin-dependent pathway. When
pH decreases during the endosome maturation, the ferric iron dissoci-
ates from the Tf and the rest of the complex returns to plasma mem-
brane. Once exposed to the neutral pH at cell surface, apotransferrin
and TfR dissociates and are ready for another round of iron uptake.
Mammals have two TfRs. TfR1 is ubiquitously expressed in almost all
types of cells, and TfR2 is predominantly expressed in hepatocytes
[14,15]. In addition to its function as a receptor for Tf, TfR2 also senses
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pression of the iron-regulatory hormone hepcidin [16,17].
One of the key factors that control efﬁcient iron uptake is the vary-
ing binding afﬁnities of Tf to iron and to TfR at different pH. In the ex-
tracellular medium, which has a pH of ~7.4, apotransferrin has very
high afﬁnity for ferric iron [18,19]. The diferric Tf binds TfR1 with
~10 and ~100 fold higher afﬁnity than that of monoferric Tf and apo-
transferrin, respectively [20]. In the acidic environment of endo-
somes, iron dissociates from Tf due to reduced binding afﬁnity
[21,22]. The resultant apotransferrin has signiﬁcantly higher afﬁnity
to TfR1 at the acidiﬁed endosomal pH [23,24]. This increased interac-
tion facilitates the recycling of apotransferrin back to the circulation.
This Tf cycle involves membrane trafﬁcking along speciﬁc cellular
compartments including plasma membrane, early endosomes, and
recycling endosomes. It is likely that each step requires speciﬁc sort-
ing machinery to ensure the efﬁciency of cycling [25]. For example,
Sec15L1, a protein identiﬁed from a hemoglobin deﬁcit (hbd)
mouse, regulates TfR1 recycling in red blood cells [26,27]. Sec15L1 lo-
calizes to the recycling endosomes and interacts with Rab11 [28]. De-
fective exocytosis, but not endocytosis, of Tf was observed in the hbd
mouse [29]. The heme synthesis defect can be rescued by supplying
the hbd reticulocytes with Fe complexed with salicylaldehyde isoni-
cotinoyl hydrazone (SIH), a membrane-permeable iron chelate that
can be taken up by cells through TfR-independent pathway [30].
Ferric iron released from the Tf–TfR complex is reduced within
endosomes. The six-transmembrane epithelial antigen of the prostate
member 3 (Steap3) and other Steap proteins may function as endoso-
mal ferrireductases in erythroid and non-erythroid cells, respectively
[31,32].
Once reduced, the iron will be transported across the endoso-
mal membrane. It is well known that the endosomal-localized
DMT1 is responsible for mobilizing iron out of endosomes [7,33].
It was recently shown that the transient receptor potential muco-
lipin 1 (TRPML1) may function as another iron release channel.
TRPML1 predominantly localizes to late endosomes and lysosomes
(LELs) [34,35]. Mutations of TRPML1 are associated with human
mucolipidosis type IV disease — a neurodegenerative lysosomal
storage disorder. Studies using patch-clamp recordings showed
that addition of Fe2+ induced large inwardly rectifying currents
on the membranes of TRPML1-positive LELs, indicative ofFig. 1. Iron uptake through transferrin cycle. Diferric Tf binds TfR on the plasma mem-
brane. The Tf–TfR complex is internalized through clathrin-dependent endocytosis.
Acidiﬁcation of endosomes by proton-ATPase lowers the afﬁnity of Tf to ferric iron,
which is subsequently released into the lumen. The released ferric iron is reduced by
Steaps and exported out of endosomes by divalent metal transporter DMT1. The tran-
sient receptor potential mucolipin TRPML1 and the zinc transporter ZRT/IRT-like pro-
tein Zip14 may also be involved in endosomal iron release. Within acidic
environment, apotransferrin remains bound to TfR. The complex is recycled to the
cell surface, where Tf dissociates from TfR. The trafﬁcking molecule Sec15L1 is required
for the efﬁcient recycling of Tf–TfR. Details of the basic trafﬁcking machinery such as
clathrin, adaptors, and Rab proteins are not shown in the ﬁgure.transport [36]. Skin ﬁbroblasts from homozygous TRPML−/− pa-
tients displayed signiﬁcantly lower Fe2+ in the cytoplasm, where-
as their lysosomes retained higher Fe2+ levels than the TRPML1+/+
or TRPML1+/− cells [36]. In addition, transport assays using
TRPML1(V432P), a mutant form that localizes to both LELs and plas-
ma membrane, indicate that TRPML1 can also transport other diva-
lent metals including Mn2+ and Zn2+, but not Fe3+. These results
suggest that TRPML1 may function as an iron transporter in endoly-
sosomal systems in parallel to DMT1. A third protein that may be im-
plicated in endosomal iron release is the zinc transporter ZRT/IRT-
like protein 14 (Zip14). Zip14 localizes to plasma membrane as
well as Tf-positive endosomes in HepG2 cells [37]. Overexpression
of Zip14 in HEK293T cells increased the iron uptake delivered by Tf,
whereas its knockdown in HepG2 cells reduced the Tf iron uptake
[37]. However, as discussed later in this review, other studies have
shown that Zip14 mainly localizes to plasma membrane. Thus, it's
more likely that Zip14 plays an important role in Tf-independent
iron uptake rather than endosomal iron translocation.
The mechanism immediately following the endosomal iron re-
lease is not well understood. Within the cytoplasm, a proportion of
iron is incorporated into the cytoplasmic iron-containing proteins
and extramitochondrial iron–sulfur (Fe–S) clusters [38–40]. Excess
amount of iron is stored in ferritin. Cytosolic ferritin is composed of
24 H- and L-subunits, and stores up to 4500 iron atoms. A cytosolic
iron chaperone poly (rC) binding protein 1 (PCBP1) and its paralog
PCBP2 may mediate the iron delivery to cytoplasmic iron-containing
proteins. PCBP1 binds ferrous iron with a stoichiometric ratio of one
PCBP1 to three iron atoms [41]. It also interacts with cytoplasmic
iron-containing proteins including ferritin, iron-dependent prolyl hy-
droxylases PHDs, and the asparaginyl hydroxylase FIH1 [41,42].
Knockdown of PCBP1 or 2 speciﬁcally impairs iron incorporation
into these metalloproteins, suggesting that PCBP1 and 2 may serve
as iron chaperones responsible for delivering iron to the cytoplasmic
proteins [41,42]. It remains to be investigated whether PCBP1 and 2
acquire iron directly from endosomal iron transporters such as DMT1.
3. Mitochondrial iron homeostasis
The mitochondrion serves as the center for cellular iron homeo-
stasis since iron is primarily consumed by this organelle for the syn-
thesis of heme and Fe–S clusters [43,44] (Fig. 2). It is likely that a
PCBP1-like cytosolic chaperone may exist to facilitate the transfer of
endosomal iron, exported by DMT1, to mitochondria. Alternatively,
the iron-loaded endosomes may directly interact with mitochondria
for targeted iron delivery. This transient “kiss-and-run” mechanism
has been observed in developing erythroid cells, which have high
iron demand for mitochondrial heme synthesis [45,46]. Although
the molecular basis is still lacking, transient interaction of two organ-
elles may bypass the cytoplasm and ensure sufﬁcient iron supply for
the heme synthesis. Intracellular ferritin may provide another source
of iron for mitochondria [47] (Fig. 2). Under iron-limiting conditions,
ferritin complexes are degraded and ferritin iron is recycled. The deg-
radation of cytosolic ferritin takes place in proteasomes or lysosomes,
depending on the type of iron chelation [48–50]. The mechanisms re-
sponsible for the transfer of ferritin iron from these compartments to
mitochondria are unclear.
By working on the anemic zebraﬁsh mutant frascati, Shaw et al.
discovered the mitochondrial iron importer mitoferrin 1 (Mfrn1;
Slc25a37) and its paralog mitoferrin 2 (Mfrn2; Slc25a28) [51]. These
two transporters, located primarily on the mitochondrial inner mem-
brane, play essential roles in supplying iron for the biosynthesis of
heme and Fe–S clusters in the mitochondria. Knockout of Mfrn1 in
mouse early erythroid cells resulted in defects in both mitochondrial
iron import and heme synthesis [51,52]. In addition to vertebrate
Mfrn, its homologs in yeast and plants also play conserved role in
transporting iron into the mitochondria. Deletion of the yeast
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the synthesis of mitochondrial Fe–S clusters and heme [53–55]. Sup-
pression of the Mfrn1 ortholog in rice, mitochondrial iron transporter
(MIT), led to a reduction in mitochondrial iron accumulation and Fe–S
cluster biogenesis [56].
The expression of Mfrn1 is regulated at both transcriptional and
posttranslational levels. The erythroid transcription factor GATA1 can
bind two cis-regulatory elements upstream of mouse Mfrn1 and medi-
ates its erythroid-speciﬁc expression [57]. During erythroid differentia-
tion, Mfrn1 protein is also stabilized by interacting with another
mitochondrial protein, the ATP binding cassette protein Abcb10 [58].
Additionally, the ﬁnal enzyme in heme synthesis pathway, ferrochela-
tase, forms an oligomeric complex with Mfrn1 and Abcb10 to enhance
the coordinated iron utilization by heme synthesis [59].
In contrast to the strong expression ofMfrn1 in hematopoietic tis-
sues, Mfrn2 is ubiquitously expressed in all tissues at low levels, sug-
gesting that it may serve as the mitochondrial iron importer in non-
erythroid cells [51]. In non-erythroid cells, these two Mfrns are func-
tionally interchangeable [60]. However, Mfrn2 does not rescue the
heme defect in Mfrn1-deﬁcient erythroid cells or frascati ﬁsh mutant
[51,60]. This is because that Abcb10 selectively interacts with and sta-
bilizes Mfrn1, but not Mfrn2, in erythroid mitochondria [58].
Iron within the mitochondria is either utilized for the biosynthesis
of heme and Fe–S clusters, or stored in mitochondrial ferritin (MtF).
MtF was identiﬁed as a Ferritin H subunit-like protein expressed in
testes and erythroid cells and localized to the mitochondrial matrix
[61]. It has both ferroxidase and iron binding activities [61,62]. Over-
expression of MtF caused iron redistribution from cytosol to mito-
chondria [62,63]. Within mitochondria, MtF sequesters iron and
limits the iron consumption by heme and Fe–S cluster synthesis
[63]. Thus, abnormal expression of MtF in erythroid cells associates
with the X-linked sideroblastic anemia [64]. Most of these observa-
tions were made in overexpression systems. Further studies are re-
quired to reveal the precise role of MtF in iron homeostasis.
Although non-erythroid cells need heme for incorporation into a
wide variety of hemoproteins such as cytochromes, erythroid tissues
have extremely high demand for heme synthesis, and thus mitochon-
drial iron supply. Heme biosynthesis is a highly conserved pathwayFig. 2.Mitochondrial iron import. The iron imported through Tf–TfR cycle can be read-
ily utilized by mitochondria. Cytosolic ferritin may also provide iron for mitochondria.
Tf iron is released into endosomes, whereas ferritin is degraded in either proteasomes
or lysosomes. Iron is delivered to mitochondrial outer membrane through unknown
mechanisms. Mitoferrin (Mfrn) imports iron into the mitochondria, where iron is ei-
ther utilized for the synthesis of heme and Fe–S clusters, or stored in mitochondrial fer-
ritin (MtF). Fe–S clusters may regulate erythroid heme synthesis through modulating
the activity of iron regulatory protein 1 and the expression of δ-aminolevulinate
synthase 2.which involves eight enzymatic reactions [44]. It is tightly controlled
by many factors such as iron availability and oxygen levels.
Mutations in heme synthesis genes result in human hematological
disorders characterized by defective cellular iron homeostasis [65].
Defects in genes relating to heme biosynthesis, such as ferrochelatase
[66] and C-terminal deletion of δ-aminolevulinate synthase 2 (ALAS2)
[67] are associated with porphyrias. In addition, proteins that impact
on the phenotypic expression of porphyrias include heme-regulated
eIF2-kinase [68], iron regulatory protein 2 (IRP2) [69], and abnormal
expression of Mfrn1 [52,70]. Previous human studies have identiﬁed
ALAS2, FXN, ABCB7, and SLC25A38 as the genetic causes of congenital
sideroblastic anemias [71,72].
Heme synthesis is also regulated by the availability of Fe–S clus-
ters (Fig. 2). Fe–S clusters are prosthetic groups that play essential
roles in basic cellular metabolism such as mitochondrial electron
transport and catalysis. Defects in the assembly of mitochondrial
Fe–S clusters are associated with mitochondrial iron overload and
blood disorders [43,73]. For example, patients with Friedreich ataxia
exhibit mitochondrial iron overload due to genetic defects in the mi-
tochondrial Fe–S cluster iron chaperone Frataxin [74]. Likewise, mu-
tations in glutaredoxin-5, a gene required for Fe–S cluster synthesis
[75], resulted in mitochondrial iron accumulation andmicrocytic ane-
mia [76,77]. The resultant mitochondrial iron accumulation may lead
to abnormal heme synthesis. In addition, Fe–S clusters may directly
control heme synthesis through regulating the activity of iron regula-
tory protein 1 (IRP1) and the expression of ALAS2, the rate limiting
enzyme in erythroid heme synthesis [78]. When the level of Fe–S
clusters is low, IRP1 associates with the iron regulatory element
(IRE) in the 5′ untranslated region (UTR) of ALAS2 mRNA, blocking
its translation as well as heme synthesis. More recently, a systems bi-
ology study found that two genes known to be involved in Fe–S clus-
ter biosynthesis, Isca1 and Iba57, are essential for erythroid heme
biosynthesis [79]. Morpholino knockdown of either gene in zebraﬁsh
resulted in profound anemia, possibly due to defects in heme
synthesis.
In addition to the functional requirement of heme and Fe–S clus-
ters within mitochondria, a large number of hemoproteins and Fe–S
containing proteins are present in extramitochondrial compartments
[80,81]. Thus, these two iron-containing cofactors must be able to exit
mitochondria. These export mechanisms may be indispensable for
maintaining mitochondrial iron homeostasis. The ATP binding cas-
sette transporter ABCB7 is functionally required for the export of mi-
tochondrial Fe–S clusters. Mutation of ABCB7 caused X-linked
sideroblastic anemia in humans [82,83]. Knockdown of ABCB7
resulted in mitochondrial iron overload accompanied with cellular
iron deﬁciency [84]. The pathway responsible for mitochondrial
heme export remains elusive. A potential porphyrin transporter
ABCB6 might be involved [85]. ABCB6 is an outer mitochondrial
membrane protein initially identiﬁed as a mammalian ortholog of
the yeast mitochondrial iron transporter ATM1 [86]. Its expression
strongly correlates with that of heme synthesis genes [79]. ABCB6 in-
teracts with both heme and porphyrin compounds [85]. Overexpres-
sion of ABCB6 in human erythroleukemia (K562) cells signiﬁcantly
increased the population of protoporphyrin IX-positive cells and the
cytosolic heme levels [85,87]. Further investigation is required to dis-
sect the biological role of ABCB6 in heme homeostasis and its subcel-
lular localization [88].
4. Trafﬁcking of non-transferrin bound iron
Although Tf cycle is indispensable for hematopoiesis, most other
cells may take up iron independent of this cycle. In hypotransferrine-
mic mice, only hematopoietic cells are deﬁcient of iron, while other
cells even exhibited iron accumulation [89]. Similarly, mice lacking
TfR1 displayed severe anemia and embryonic lethality due to iron de-
ﬁciency in erythroid tissues, but the development of other organs
Table 1
Candidate molecules involved in the uptake of non-transferrin bound iron.
Name of protein or
molecule
Description and
other names
Function or putative
function
Reference
Catechol Mammalian
siderophore
[92]
2,5-DHBA 2,5-dihydroxybenzoic
acid
Mammalian
siderophore
[93]
Lipocalin 2 α2-microglobulin-
related protein,
neutrophil gelatinase-
associated lipocalin,
24p3, siderocalin
Mammalian
siderophore-iron
binding protein
[92,93,101,
102,108]
BOCT Brain type organic cation
transporter
Lipocalin 2 receptor [110]
Megalin Low-density lipoprotein
receptor 2
Lipocalin 2 receptor [109]
Scara5 Scavenger receptor class
A member 5
L-ferritin receptor [91]
Tim-2 T cell immunoglobulin
and mucin domain-
containing protein-2
H-ferritin receptor
in mouse
[119,120]
TfR1 Transferrin receptor 1 H-ferritin receptor
in human
[123]
Zip14 ZRT/IRT-like protein 14 Fe2+ transporter [126,127]
DMT1 Divalent metal ion
transporter 1
Fe2+ transporter [129–131]
TRPC6 Transient receptor
potential protein
canonical 6
Regulator of NTBI
uptake
[135]
LVDCC L-type voltage-
dependent calcium
channel
Regulator of NTBI
uptake
[136]
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showed that TfR1−/− stem cells can populate many organs including
bladder, gonad, liver, lung, kidney, and intestine [91], indicating that
these cells are able to utilize iron through mechanisms that are dis-
tinct from Tf–TfR pathway. Non-transferrin bound iron (NTBI) refers
to the circulating pool of iron that is not bound to Tf. A number of
molecules, such as citrate, acetate, and albumin, have been proposed
to bind NTBI. It was recently found that mammals secrete
siderophore-like compounds that can bind iron in the circulation
[92,93]. The cellular uptake of siderophore iron, heme, and ferritin
may represent main iron uptake pathways that are independent of
Tf cycle (Table 1). Heme trafﬁcking is not covered in this review
since it is discussed by Drs. Iqbal Hamza and Harry Dailey in this issue.
4.1. Lipocalin–siderophore system
Bacteria, fungi, and graminaceous plants are able to obtain iron by
secreting a group of small, high-afﬁnity iron binding molecules called
siderophores [94,95]. Hydroxamic acids and catechols are common
functional moieties found in siderophores. Once loaded with Fe3+,
these siderophores can be taken up by cells through cell surface
receptors.
Vertebrate animals also produce siderophores. A recent chemical
screen on protein-free urine ﬁltrates identiﬁed a group of active
catechol-like compounds with high afﬁnity for Fe3+ [92]. Devireddy
et al. independently discovered 2,5-dihydroxybenzoic acid (DHBA) as
another iron-binding compound that is excreted by murine pro-B lym-
phocytic FL5.12 cells [93]. 2,5-DHBA is analogous to 2,3-DHBA, the func-
tional core in bacterial siderophore enterobactin [95]. Importantly,
EntA, the enzyme responsible for the synthesis of bacterial 2,3-DHBA,
is conserved in vertebrates as a β-hydroxybutyrate dehydrogenase
(BDH2) [93]. Silencing of BDH2 in mouse erythroleukemia (MEL) cells
impaired the production of heme and hemoglobin [93]. BDH2 knock-
down with morpholinos in zebraﬁsh resulted in hypochromic anemia
[93]. Taken together, these results suggest that vertebrate siderophores
may contribute to iron homeostasis in erythroid tissues.
Vertebrate siderophores bind lipocalin 2,which is also known asα2-
microglobulin-related protein, neutrophil gelatinase-associated lipoca-
lin, 24p3, and siderocalin. Lipocalin 2 belongs to lipocalin family — a
group of small, secreted proteins that bind small hydrophobic com-
pounds [96,97]. Human lipocalin 2 is highly expressed in bone marrow
and trachea [98]. The expression and secretion of lipocalin 2 is also in-
duced under pathological conditions such as renal injury [99,100]. Lipo-
calin 2 was shown to bind catechol-type siderophores, and the binding
afﬁnity is affected by its iron status [92,93]. For example, the presence of
Fe3+ allosterically increased the catechol–lipocalin 2 interaction by
~100 fold [92].When introduced separately intomouse serum, lipocalin
2 and catechol-Fe3+ quickly associate [92].
Lipocalin 2 is also able to bind siderophores secreted by bacteria or
mycobacteria with high afﬁnity. When expressed in Escherichia coli,
lipocalin 2 was copuriﬁed with bacterial siderophore, ferric entero-
bactin [101]. Additionally, lipocalin 2 can bind soluble siderophores
from Mycobacterium tuberculosis, carboxymycobactins [102]. Subse-
quent studies showed that it plays an important role in antibacterial
innate immune response by sequestering iron. Its expression was sig-
niﬁcantly induced by lipopolysaccharide and infection [103,104].
Presence of lipocalin 2 speciﬁcally inhibits bacteria growth in an
enterobactin-dependent manner, whereas lipocalin 2 deﬁcient mice
had signiﬁcantly increased bacteria burden and lethality upon infec-
tion with pathogenic E. coli [103,105]. Interestingly, these lipocalin 2
knockout mice appear to have normal organ development [103], sug-
gesting that the contribution of siderophore iron to organogenesis
may be dispensable during the development, or other pathways
may exist to mediate the uptake of siderophore iron. Another lipoca-
lin, lipocalin Q83, originally identiﬁed in quail ﬁbroblasts, was also
shown to bind siderophore enterobactin with afﬁnity comparable tothat of lipocalin 2 [106]. Lipocalin Q83 has 87% and 23% sequence
identities to chicken homolog Ch21 and human lipocalin 2, respec-
tively [106]. However, this lipocalin also binds unsaturated fatty
acids, suggesting that it may play a dual role in the metabolism of
iron and fatty acid [107].
Mammalian cells are capable of utilizing extracellular lipocalin 2-
siderophore-Fe3+ complex for iron homeostasis. Bao et al. showed
that the complex formed in mouse serum could be captured by kid-
ney, lung, and liver [92]. Incubation of 59Fe-labeled lipocalin 2 with
Madin Darby Canine Kidney (MDCK) and other kidney-derived cell
lines resulted in a time-dependent accumulation of cellular 59Fe
[108]. This iron source can contribute to cellular iron metabolism
since iron-loaded lipocalin 2 induced the ferritin expression and re-
pressed TfR1 expression [108]. Similar to Tf–TfR system, lipocalin 2–
catechol–Fe3+ complexes are stable at neutral pH, and dissociate
upon acidiﬁcation of the environment [92]. After iron is released
within acidic endosomes, lipocalin 2 is not degraded, suggesting
that it may be recycled [108]. While the mechanisms of iron release
and protein recycle are likely to be similar to Tf cycle, the internaliza-
tion step is different. Upon entering the cells, the majority of lipocalin
2 is localized to the compartments that are distinct from Tf [108]. Fur-
thermore, the uptake of lipocalin 2 and Tf does not compete with each
other [108], suggesting that other receptors exist for the internaliza-
tion of lipocalin 2–catechol–Fe3+ complexes.
Two cell surface receptors may be implicated in the trafﬁcking of
lipocalin 2. Megalin, also known as low-density lipoprotein receptor
2, is an endocytic molecule that binds both apo- and hololipocalin 2
with high afﬁnity [109]. A rat yolk sac cell line expressing megalin
speciﬁcally takes up lipocalin-2 — an activity that is blocked by anti-
megalin antibody [109]. By screening the cDNA library of murine
FL5.12 cells for lipocalin 2 binding activity, Devireddy et al. discov-
ered brain type organic cation transporter (BOCT) as another lipocalin
2 receptor [110]. BOCT is widely expressed in mouse tissues such as
kidney, placenta, and heart. HeLa cells stably expressing BOCT exhib-
ited speciﬁc internalization of 32P-labeled or ﬂuorophore-labeled
lipocalin 2. Incubation of BOCT-expressing HeLa cells with iron-
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dicated by changes in ferritin expression and intracellular iron levels.
Interestingly, when BOCT-expressing cells were exposed to apoli-
pocalin 2, the intracellular iron levels were reduced [110]. This result
is consistent with a study by Li et al. which show that iron-loaded
lipocalin 2 donates iron whereas apolipocalin 2 chelates iron when
incubating with HEK293 cells [111]. Iron chelation of apolipocalin 2
within the cells is dependent on the presence of siderophores.
When the siderophore synthesis gene BDH2 was knocked-down in
murine FL5.12 cells, apolipocalin 2 had dramatically reduced activity
to bind or chelate intracellular iron [93]. These results suggest that
mammalian siderophores could also associate with iron in the cyto-
plasm. Thus, lipocalin 2 may play a dual role in regulating cellular
iron homeostasis.
4.2. Secreted form of ferritin and associated receptors
The iron-storage protein ferritinmay also be involved in cellular iron
import. Ferritin is present in the cytoplasm, nucleus andmitochondrion
within the cell. It is also found in the circulation, and the levels of serum
ferritin are widely used to monitor the body iron status in humans.
Cohen et al. showed that mouse serum ferritin forms a complex of 24
subunits, which are composed of mostly L-ferritin with detectable
levels of H-ferritin [112]. The majority of serum ferritin comes from
secretion by macrophages [112,113], the cells primarily responsible
for iron recycling from senescent red blood cells. The ferritin chains
are secreted through classic secretory pathway and this may bemediat-
ed by the ER-targeting sequence contained at the amino terminus
[114,115]. The secretion is inducible under conditions when ferritin
proteins are produced but the cytoplasmic iron is limiting [114].
A number of studies have shown that cells can utilize extracellular
ferritin as an iron source. Cationic ferritin, a derivative of horse spleen
ferritin, can be endocytosed to lysosomes for degradation in human
ﬁbroblast [116]. The macrophage-derived ferritin iron can be utilized
by hepatocytes and erythroid precursor cells for the production of
heme and hemoglobin [113,117]. Supplementation of H-ferritin can
stimulate the growth and differentiation of oligodendrocyte progeni-
tor cells that were deprived of Tf [118].
Li et al. found that mesenchymal tissues, capsule and stroma of the
kidney are able to take up iron independent of TfR1, and further iden-
tiﬁed the scavenger receptor class A member 5 (Scara5) as a receptor
for L-ferritin in the kidney [91]. Transient expression of Scara5 in Trvb
cells, a cell line that lacks Scara5 and TfR1, resulted in the internaliza-
tion of L-ferritin. Knockdown of Scara5 in mouse Sertoli cell line
(MSC-1) cells by shRNA inhibited the ferritin endocytosis. The
Scara5-expressing cells can also internalize haptoglobin–hemoglobin
complex, but not H-ferritin or Tf. Uptake studies with 59Fe-Ferritin
conﬁrmed that the imported ferritin iron stimulates the growth and
proliferation of Trvb and capsular cells.
Two molecules were suggested to function as receptors for H-
ferritin. Mouse T cell immunoglobulin and mucin domain-
containing protein-2 (Tim-2) may serve as a receptor for H-ferritin
in splenic T cells and oligodendrocytes [119,120]. TIM-2 localizes to
plasma membrane and endosomes [119,121]. It speciﬁcally interacts
with and internalizes H-ferritin, but not L-ferritin [119,120]. TCMK-
1, a mouse kidney epithelial cell line, transfected with Tim-2 had sig-
niﬁcantly increased uptake of 55Fe-loaded H-ferritin [121]. The up-
take was conﬁrmed in a mouse lymphocyte cell line (A20).
Receptor-mediated endocytosis is responsible for the internalization
of H-ferritin [121]. Since serum ferritin is present as 24-subunit nano-
cages [112], they need to be disassembled before receptor binding
and internalization take place. It is unclear how ferritin disassembly
is achieved extracellularly. Upon reaching lysosomes, H-ferritin is de-
graded and the released iron enters the cytoplasmic iron pool [121].
A distinct H-ferritin receptor may exist in humans since Tim-2 is
not present in human genome [122]. In addition to serving as Tfreceptor, TfR1 was found to be a primary H-ferritin receptor in retic-
ulocytes, activated lymphocytes, and most other cell lines in humans
[123]. It speciﬁcally interacts with H-ferritin, but not L-ferritin. The
interaction can be partially inhibited by the presence of diferric Tf.
The H-ferritin–TfR1 complex is endocytosed through an endocytic
pathway that is similar to the Tf cycle. However, within the
endosomes, H-ferritin is sorted to lysosomes for degradation whereas
Tf returns to the plasma membrane.
4.3. Zip14
Zip14 was ﬁrst identiﬁed as a plasma membrane protein with zinc
transport activity [124,125]. Liuzzi et al. found that in addition to zinc,
ferrous iron is also transported by Zip14 [126]. Expression of Zip14 in
Sf9 cells signiﬁcantly increased the uptake of 59Fe, which can be
inhibited by the addition of either a cell-impermeant ferrous chelator
or zinc. Furthermore, knockdown of Zip14 in mouse hepatocyte
AML12 cells signiﬁcantly reduced the uptake of iron. Expression of
Zip14 in Xenopus oocytes stimulated the uptake of Fe2+, but not
Fe3+, in a pH-dependent and calcium-dependent manner [127]. In
addition to Zn2+ and Fe2+, Zip14 also transports Cd2+ and Mn2+
[127]. Zip14 is regulated by the hereditary hemochromatosis protein
HFE post translationally [128]. Studies on both HepG2 and HeLa
cells showed that overexpression of HFE reduced the uptake of NTBI
through decreasing Zip14 protein level [128].
4.4. Other molecules involved in the uptake of NTBI
The well-studied iron transporter DMT1 mediates the uptake of
ferrous iron in the intestine [7]. A number of in vitro studies suggest
that DMT1 is also involved in the uptake of Fe2+ in other cells. For ex-
ample, Fe3+ can be reduced by ascorbate and the Fe2+ accumulates
in primary rat astrocytes in a DMT1-dependent manner [129]. Over-
expression of DMT1 signiﬁcantly increased the uptake of Fe2+ inde-
pendent of Tf cycle in hepatoma and Chinese hamster ovary cells
[130,131]. DMT1 also localizes weakly on the plasma membrane, in
addition to the cytoplasmic localization, of hepatoma cells [130].
Calcium channels may also be implicated in the regulation of NTBI
transport. Extracellular calcium has been shown to stimulate the up-
take of NTBI by HeLa and K562 cells [132]. Transient receptor poten-
tial protein canonical 6 (TRPC6), an α1-adrenoceptor-operated
calcium channel, plays a predominant role in store-independent Ca2+
entry [133,134]. Overexpression of TRPC6 in HEK293 cells decreased
the ﬂuorescence of calcein, an indicator that is negatively regulated by
cytoplasmic iron levels [135]. Another calcium channel involved in
iron homeostasis is L-type voltage-dependent calcium channel
(LVDCC). Blocking of LVDCC activity with amlodipine and verapamil
in chronic iron-overload mice reduced the myocardial iron levels,
while overexpression of α1-subunit of LVDDC increased the iron depo-
sition in cardiomyocytes [136]. Similarly, the use of T-type calcium
blocker efonidipine reduced the iron uptake by cultured cardiomyo-
cytes [137]. Although it was proposed that the calcium channels trans-
port a wide range of divalent substrates including Fe2+ [138,139], they
may function as regulators, rather than transporters, in iron homeosta-
sis. Ludwiczek et al. showed that the dihydropyridine-based LVDCC
blocker nifedipine regulated DMT1 activity— amechanism thatwas re-
sponsible for mobilizing iron out of liver in iron-overload mice [140].
Future investigations using systems other than inhibitors or overex-
pressed cell linesmay help to elucidate the physiological role of calcium
channels in iron metabolism.
4.5. Utilization of NTBI by mitochondria
Some forms of NTBI may contribute to mitochondrial iron homeo-
stasis. For example, silencing of vertebrate siderophore synthesis
gene BDH2 reduced the mitochondrial iron content as well as heme
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tochondria. Similarly, iron delivered through extracellular ferritin
may also be consumed by mitochondria for the production of heme
and hemoglobin [113,117,141]. Evidence is still lacking regarding
the signiﬁcance of iron uptake through Zip14 and calcium channels
on mitochondrial iron metabolism. Furthermore, it is unclear whether
siderophore iron, ferritin iron, and Tf-iron trafﬁc to mitochondria
through similar molecular pathways.
5. Current approaches in identifying iron trafﬁcking regulators
Studies with model organisms zebraﬁsh, mice, rats, and yeast have
greatly improved the understanding of iron metabolism. Many iron
trafﬁcking molecules and regulators were discovered through such
strategies as forward genetics, reverse genetics, expression cloning,
bioinformatics, and proteomics (Table 2).
5.1. Phenotype-driven approaches
A number of novel genes that play fundamental roles in iron me-
tabolism were identiﬁed by mutagenesis screens in zebraﬁsh and
mouse [142–144]. The only known vertebrate iron exporter, ferropor-
tin1, was initially discovered through characterizing the zebraﬁsh
mutant weissherbst [9]. This iron exporter was also independently
identiﬁed using other approaches such as subtractive cloning and
RNA pull-down [8,10]. Studies on another zebraﬁsh mutant frascati
led to the identiﬁcation of the high-afﬁnity mitochondrial iron im-
porter mitoferrin 1 [51]. Additionally, the iron-related functions of
the endosomal ferrireductase Steap3 and the exocyst protein
Sec15L1 were uncovered by studying the anemic mutant mice
nm1054 and hbd, respectively [26,31]. Current tools such as the
next-generation sequencing may be applied to accelerate the identiﬁ-
cation of genetic lesions in animal mutants or human patients with
blood disorders. Classical human genetics recently identiﬁed the mi-
tochondrial glycine transporter, SLC25A38, whose defect results in
sideroblastic anemia [145].
5.2. Gene-driven approaches
This type of approaches usually starts with a set of interesting
genes obtained from DNA sequencing, gene expression studies, or
bioinformatics analysis. Genes with similar expression proﬁles
under a certain biological condition are more likely to be involved
in the same biological pathway. The phenotypes and functions of
these genes can be examined through targeted mutagenesis or gene
silencing. To identify new components in mitochondrial iron trafﬁck-
ing, Nilsson et al. screened for the mitochondrial genes that wereTable 2
Identiﬁcation of regulators of iron homeostasis.
Function Reference
Phenotype-driven
DMT1 Divalent iron transporter [6, 9]
ferroportin1 Vertebrate iron exporter [9]
mitoferrin 1 Mitochondrial iron importer [51]
Steap3 Endosomal ferrireductase [31]
Sec15L1 Trafﬁcking regulator of TfR1 [26]
Gene-driven
Slc25a39 Regulator of heme synthesis [79]
Slc22a4 Regulator of heme synthesis [79]
Tmem14c Regulator of heme synthesis [79]
Expression cloning
DMT1 Divalent iron transporter [7]
PCBP1 Cytosolic iron chaperone [41]
BOCT Lipocalin 2 receptor [110]
Proteomics
Abcb10 Regulator of mitoferrin 1 [58]coordinately coexpressed with the heme synthesis genes from
~35,000 public available cDNA microarrays [79]. Five novel genes
(Slc25a39, Slc22a4, Tmem14c, Isca1, and Iba57) were found to be es-
sential for heme synthesis and blood development. Morpholino
knockdown of these genes resulted in anemia in zebraﬁsh, and silenc-
ing of SLC25A39 in differentiating MEL cells strongly reduced heme
synthesis, suggesting that they may be involved in mammalian mito-
chondrial iron homeostasis.
5.3. Expression cloning
This strategy combines the advantages of both forward and re-
verse genetics. Usually, after the initial functional screen, the identity
of the gene can be quickly uncovered. For example, the screen of a rat
duodenal cDNA library in oocytes and a human liver cDNA library in
yeast led to the discoveries of the proton-coupled Fe2+ transporter
DMT1 and the cytosolic iron chaperone PCBP1, respectively [7,41].
DMT1 was also simultaneously identiﬁed as an iron transporter by
analyzing the microcytic anemic mk mice [6]. In addition, by screen-
ing a cDNA library prepared from murine FL5.12 cells, Devireddy et
al. found that BOCT, the brain type organic cation transporter, acts
as a receptor for lipocalin 2 [110].
5.4. Proteomics
Proteomic analysis has been widely used in identifying protein–
protein interactions. One successful case of this strategy in iron traf-
ﬁcking is the functional characterization of Abcb10. Abcb10 has long
been proposed as a mitochondrial transporter in erythroid tissues
[146,147]. The proteomic study by Chen et al. revealed that Abcb10
regulates iron metabolism by stabilizing the mitochondrial iron im-
porter mitoferrin 1 [58]. Furthermore, this study showed that the fer-
rochelatase interacts with mitoferrin complex in order to enhance the
iron utilization by heme synthesis [59].
6. Perspectives
In the near future, we anticipate that additional components will
be identiﬁed in iron metabolism by using the combination of genetic,
genomic, systems biology, and biochemical approaches. Future stud-
ies on noncanonical iron uptake pathways will provide important in-
sights in iron homeostasis in nonerythroid tissues. It is an exciting
time for current and new investigators to further our understanding
of iron homeostasis.The putative porphyrin transporter, ABCB6, pre-
viously ascribed to be essential for mitochondrial porphyrin uptake
was recently shown to be dispensable for erythropoiesis and speciﬁes
the new blood group system Langereis (V. Helias, et al. Nat. Genet.
(2012), in press. doi:10.1038/ng.1069). Human patients with somatic
mutations in ABCB6 have ocular colobomas (L. Wang, et al. Am. J.
Hum. Genet. 90 (2012) 40–48).
Note added in proof
The putative porphyrin transporter, ABCB6, previously ascribed to be
essential for mitochondrial porphyrin uptake was recently shown to be
dispensable for erythropoiesis and speciﬁes thenewblood group system
Langereis (V. Helias, et al. Nat. Genet. (2012), in press. doi:10.1038/
ng.1069). Humanpatientswith somaticmutations in ABCB6 have ocular
colobomas (L. Wang, et al. Am. J. Hum. Genet. 90 (2012) 40–48).
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